Publications en collaboration avec des chercheurs de Hospital Universitario de Salamanca (36)

2024

  1. 18F-FDG-PET/CT response after first-line treatment as a prognostic factor for survival in peripheral T-cell lymphoma: a Spanish retrospective study

    Expert Review of Hematology, Vol. 17, Núm. 1-3, pp. 95-100

  2. Comparing R-Bendamustine vs. R-CHOP Plus Maintenance Therapy as First-Line Systemic Treatment in Follicular Lymphoma: A Multicenter Retrospective GELTAMO Study

    Cancers, Vol. 16, Núm. 7

  3. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance

    Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256

  4. Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy

    Frontiers in Oncology, Vol. 14

  5. Rationale and design of RESILIENCE: A prospective randomized clinical trial evaluating remote ischaemic conditioning for the prevention of anthracycline cardiotoxicity

    European Journal of Heart Failure

  6. Real-World Experience with Isavuconazole in Allogeneic Stem Cell Transplantation in Spain

    Transplantation and Cellular Therapy, Vol. 30, Núm. 10, pp. 1033.e1-1033.e8

  7. The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

    Blood cancer journal, Vol. 14, Núm. 1, pp. 74

2023

  1. Accuracy and prognostic impact of FDG PET/CT and biopsy in bone marrow assessment of follicular lymphoma at diagnosis: A Nation-Wide cohort study

    Cancer Medicine, Vol. 12, Núm. 6, pp. 6536-6546

  2. LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors

    Frontiers in Immunology, Vol. 14

  3. One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients

    Blood Cancer Journal, Vol. 13, Núm. 1

  4. Peripheral T-cell lymphoma with a T follicular-helper phenotype: A different entity? Results of the Spanish Real-T study

    British Journal of Haematology, Vol. 203, Núm. 2, pp. 182-193

  5. Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients

    Viruses, Vol. 15, Núm. 10

2022

  1. Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study

    Haematologica, Vol. 107, Núm. 11, pp. 2675-2684

  2. Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 11, pp. 1196-1205

  3. Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study

    European Journal of Cancer, Vol. 174, pp. 243-250

  4. SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group

    American Journal of Hematology, Vol. 97, Núm. 1, pp. 30-42

2021

  1. Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study

    Cancer Medicine, Vol. 10, Núm. 21, pp. 7629-7640

2019

  1. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)

    Annals of Oncology, Vol. 30, Núm. 4, pp. 612-620

  2. Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH)

    European Journal of Haematology, Vol. 102, Núm. 6, pp. 465-471

  3. Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant

    Biology of Blood and Marrow Transplantation, Vol. 25, Núm. 9, pp. 1825-1831